ReviewInternational journal of nanomedicine2025
Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Chelerythrine: a novel candidate for targeting miR-21/PTEN/PI3K/AKT in nasopharyngeal carcinoma.Journal of translational medicine · 2026Article
- A closed-loop comprehensive analysis of global burden data, future projections, risk factors, and molecular mechanisms on nasopharyngeal carcinoma.International journal of surgery (London, England) · 2026Article
- Oxidative Stress-Guided Gold Nanoparticles for Cancer Theranostics.Antioxidants (Basel, Switzerland) · 2026Review
- A bibliometric analysis of the evolution of nanotechnology research in precision theranostics for nasopharyngeal carcinoma.Discover nano · 2026Article
- The Role of miRNAs in Regulating Neurovascular Unit Homeostasis: Bidirectional Communication and Therapeutic Insights in Ischemic Stroke.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) remains a major clinical challenge due to its high resistance to conventional therapies such as chemotherapy and radiotherapy. Nanoparticle (NP)-based technologies have emerged as promising tools to enhance the efficacy of NPC treatment through mechanisms like radiosensitization and photothermal therapy. This review discusses the potential of NPs, particularly metal-based nanoparticles (gold and iron oxide), in improving the therapeutic outcomes of radiotherapy by overcoming tumor hypoxia and increasing radiation absorption. Additionally, we explore the application of NPs in photothermal therapy, wherein nanoparticles absorb light and generate localized heat to target tumor cells with precision. NPs are also playing an increasingly vital role in early diagnosis and real-time imaging, enabling more effective monitoring and personalized treatment. Despite the promising potential, challenges as nanoparticle biocompatibility, toxicity, and efficient targeting remain obstacles for clinical translation. In this review, we aim to provide a comprehensive summary of the current state of targeted nanoparticle-based interventions in NPC therapy and to outline the potential for these technologies to improve therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.